Bis docetaxel (D) +/- estramustine (E) as first line chemotherapy for patients (PTS) with hormone-refractory advanced prostate cancer (HRPC). A multicentric Italian phase II randomized trial
ANNALS OF ONCOLOGY(2006)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要